Oncternal Therapeutics, Inc.
ONCT · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $3,907 | $20,779 | $27,519 | $31,603 |
| - Cash | $13,079 | $6,382 | $6,396 | $6,697 |
| + Debt | $191 | $235 | $278 | $318 |
| Enterprise Value | -$8,981 | $14,632 | $21,401 | $25,224 |
| Revenue | $0 | $801 | $569 | $297 |
| % Growth | -100% | 40.8% | 91.6% | – |
| Gross Profit | $0 | -$5,100 | -$5,490 | -$6,373 |
| % Margin | – | -636.7% | -964.9% | -2,145.8% |
| EBITDA | -$8,681 | $0 | $0 | -$9,193 |
| % Margin | – | 0% | 0% | -3,095.3% |
| Net Income | -$8,464 | -$8,559 | -$8,388 | -$9,164 |
| % Margin | – | -1,068.5% | -1,474.2% | -3,085.5% |
| EPS Diluted | -2.86 | -2.89 | -2.83 | -3.11 |
| % Growth | 1% | -2.1% | 9% | – |
| Operating Cash Flow | -$6,953 | -$5,822 | -$7,438 | -$6,419 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6,953 | -$5,822 | -$7,438 | -$6,419 |